The short answer
Retatrutide is an investigational peptide that binds and activates three receptors involved in metabolism: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon receptor. It is often called a triple agonist, because an agonist is a molecule that activates a receptor. Semaglutide acts on GLP-1 alone and tirzepatide acts on GLP-1 and GIP, so retatrutide adds a third pathway.
It is given in trials as a once weekly injection, which reflects a long half life. For background on the compound itself, see [[what retatrutide is|/blog/retatrutide]].
Gut hormones and the incretin effect
After a meal, the gut releases hormones that tell the body food has arrived. GLP-1 and GIP are the two main incretins. They raise insulin release when blood glucose is high, which is why they have been studied for type 2 diabetes. The third hormone, glucagon, is made in the pancreas and normally acts in the opposite direction to insulin when glucose is low.
Each hormone binds its own receptor on cells in the pancreas, brain, liver, fat tissue and gut. Retatrutide is built to activate all three receptors from one molecule rather than relying on three separate compounds.
The GLP-1 receptor
In published research, activating the GLP-1 receptor increases insulin release in a glucose dependent way, slows gastric emptying and acts on appetite centres in the brain so that people report feeling full sooner. These effects underlie the weight and glucose findings seen with semaglutide and related peptides. They are also behind the nausea and other gastrointestinal effects that these medicines share. See [[side effects reported in the retatrutide trials|/blog/retatrutide-side-effects-trials]].
The GIP receptor
GIP is a second gut hormone that also stimulates insulin release. Research on tirzepatide suggests that adding GIP receptor activity can add to the metabolic effect of GLP-1 activity alone. The exact contribution of GIP is still under investigation, and researchers disagree about how much of the benefit comes from GIP itself rather than from the combination.
The glucagon receptor
Glucagon is best known for raising blood glucose, which is why adding it to a weight focused peptide looks counterintuitive. In research it is also linked to higher energy expenditure and to changes in how the liver handles fat. The GLP-1 and GIP activity is thought to balance the glucose raising effect of glucagon receptor activation. This third pathway is what separates retatrutide from tirzepatide.
Eli Lilly reports that preclinical and early phase data suggest retatrutide may reduce food intake and may help maintain energy expenditure during weight loss. These are described as suggestions from early data, not settled mechanisms in people.
How strongly it acts on each receptor
Retatrutide does not act equally on the three receptors. According to Eli Lilly Medical Information, in laboratory assays it has about 8.9 times the potency of human GIP at the human GIP receptor, about 2.5 times less potency than human GLP-1 at the GLP-1 receptor, and about 2.9 times less potency than human glucagon at the glucagon receptor. In plain terms, it is a strong GIP activator and a somewhat weaker activator of the other two than the natural hormones. These are in vitro figures, and they do not translate directly into effects in people.
Why it lasts a week
Natural GLP-1 is broken down within minutes. Retatrutide is a modified peptide designed to resist breakdown. Eli Lilly reports a half life of approximately 6 days, with peak concentration reached between 12 and 72 hours after a dose. That long half life is why trials use weekly dosing. As with other peptides, quality, purity and storage matter in the laboratory. See our guides to [[reading a certificate of analysis|/blog/peptide-certificate-of-analysis]] and [[storing research peptides|/blog/how-to-store-research-peptides]].
Why combine three pathways
The idea is that each receptor contributes a different part of the metabolic response, so activating them together could give a larger effect than one alone. Phase 2 data in the [[New England Journal of Medicine|https://www.nejm.org/doi/full/10.1056/NEJMoa2301972]] reported mean weight reductions of up to 24.2% at 48 weeks in the highest dose group, and phase 3 results announced by Eli Lilly in July 2026 reported up to 22.6% at 80 weeks. Different trials, populations and durations cannot be compared directly. See [[retatrutide trial results explained|/blog/retatrutide-trial-results]] and [[dose response in the trials|/blog/retatrutide-dose-response-trials]].
What is still unknown
Mechanism studies describe what the receptors do, not how any one supplied material behaves. The relative role of each receptor, long term effects and the best use are active research questions. Retatrutide has no UK marketing authorisation. See [[is retatrutide legal in the UK|/blog/is-retatrutide-legal-uk]].
References and evidence context
Eli Lilly, retatrutide phase 3 TRIUMPH-2 and TRIUMPH-3 results, news release, 23 July 2026
Eli Lilly Medical Information, What is the mechanism of action of retatrutide
Figures are as reported in the sources named at the time of writing. Phase 3 figures come from the sponsor news release, so check the peer reviewed papers for full methods and safety tables when published. This is general information about published research, not medical advice.
Frequently asked questions
How does retatrutide work?
It activates the GLP-1, GIP and glucagon receptors together. In published research the three pathways affect appetite, insulin release, energy use and liver fat.
Why is it called a triple agonist?
An agonist activates a receptor. Retatrutide activates three, so it is called a triple agonist.
How is retatrutide different from tirzepatide?
Tirzepatide activates GLP-1 and GIP receptors. Retatrutide also activates the glucagon receptor. See the full comparison.
How long does retatrutide last in the body?
Eli Lilly reports a half life of approximately 6 days, which is why trials use once weekly injections.
Is retatrutide approved?
No. It is investigational and has no UK marketing authorisation.
Important information
Research use only. Not a medicine, not a supplement, not approved for human or animal use.
Cambridge Health™ does not provide usage, dosage, reconstitution or administration guidance for any product. Product information on this page is provided for research and educational context only.
- Supplied strictly for laboratory and analytical research use. Not for human or animal consumption.
- No medical advice, treatment guidance or personal use recommendations are provided.
- Buyers are solely responsible for ensuring that the purchase, import, handling and use of research materials is lawful in their jurisdiction.
Supplied for laboratory research use only. Not a licensed medicine and not approved for human or animal use.
Related
Enquire about research supply
Cambridge Health supplies retatrutide research vials and the RetaPen research pen for laboratory research only.